Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.

The funding mechanism was renamed from the 'Ibogaine Development Revolving Fund' to the 'Ibogaine Intellectual Property Account' and is now located in the Office of the State Treasurer.

The official short title of the act was changed from 'Oklahoma Breakthrough Therapy Act' to 'Oklahoma Breakthrough Therapy Act' (minor wording adjustment in the short title clause).

The section number for codification in the Oklahoma Statutes was changed from Section 2-806.1 to Section 2-806.

The bill header was updated to reflect it is the 'Floor Version' rather than the 'Committee Substitute'.

The bill header was updated from 'Engrossed' to 'Committee Substitute' to reflect Senate Committee amendments.

Minor formatting and punctuation adjustments were made to the short title and section headers for consistency.

Some phrasing was slightly adjusted in the definitions and contract requirements sections, but the core obligations for drug developers and the Department of Health remain the same.

Removed all references to the 'Ibogaine Development Revolving Fund' and replaced them with an 'Ibogaine Intellectual Property Account'.

Modified the requirement for the State Department of Health to deposit proceeds from intellectual property into the new Intellectual Property Account instead of the old Revolving Fund.

Changed the bill title from 'Oklahoma Breakthrough Therapy Act' to 'Oklahoma Breakthrough Therapy Act' (minor formatting adjustment) and updated the codification section numbers in the statutes.

Added explicit creation of the 'Ibogaine Development Revolving Fund' and provisions for budgeting and expenditure of monies for a specified purpose.

Modified the contract negotiation requirements to ensure the state's share of intellectual property proceeds is remitted to the Department and deposited into the new revolving fund.

Adjusted the bill's title and summary to reflect the new revolving fund structure and the specific budgeting authority granted to the State Department of Health.

Reporting recipients were changed from the Legislature only to include the Governor, Senate President Pro Tempore, and House Speaker.

The name of the funding mechanism was updated from 'Ibogaine Intellectual Property Account' to 'Ibogaine Development Revolving Fund'.

Section numbers were updated to align with the final codification (e.g., Section 2-806.1 through 2-806.4) and the bill title was expanded to include the new fund name.

The enrolled version includes additional sponsors (May and Pae of the House, and Frix of the Senate) compared to the original introduction.